Measurement of serum p53 protein in patients with small cell lung cancer and results of its clinicopathological evaluation

Yoshihiko Segawa, Nagio Takigawa, Koichi Mandai, Yoshinobu Maeda, Ichiro Takata, Nobukazu Fujimoto, Kenji Jinno

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Serum p53 protein levels were measured in 36 patients with small cell lung cancer (SCLC) and 35 patients with benign lung diseases in order to evaluate the relationship of these levels to clinicopathological features of SCLC. Serum levels of p53 protein were measured by an enzyme-linked immunosorbent assay. p53 protein level was 23.92 ± 6.78 pg/ml in patients with SCLC, and similar to that (17.47 ± 2.86 pg/ml) in patients with benign lung diseases. By the clinical stage of SCLC, the mean level of p53 protein was 16.68 ± 4.62 pg/ml in 21 patients with limited disease, and lower than that in 15 patients with extensive disease (34.05 ± 14.84 pg/ml)(P = 0.23). The levels of p53 protein were not correlated with age, smoking index, or presence of cancer history for patients with SCLC. However, immunohistochemical examination disclosed a mild correlation between the expression of p53 protein by SCLC tumor and p53 protein serum level (r = 0.45, P = 0.02). Two patients with SCLC had an elevated serum level of p53 protein (> 2 S.D. above the mean for benign lung diseases). However, measurement of p53 protein serum level was not found to be clinically useful for detection of SCLC.

Original languageEnglish
Pages (from-to)229-238
Number of pages10
JournalLung Cancer
Volume16
Issue number2-3
DOIs
Publication statusPublished - Mar 1997

    Fingerprint

Keywords

  • enzyme-linked immunosorbent assay
  • immunohistochemistry
  • lung cancer
  • p53 gene
  • serum p53 protein
  • small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this